Results 181 to 190 of about 22,079 (225)

Composite grey matter fingerprints for genetic frontotemporal dementia. [PDF]

J Neurol Neurosurg Psychiatry
Bouzigues A, Campana G, Joulot M, Gensollen N, Russell LL, Foster PH, Ferry-Bolder E, Van Swieten JC, Jiskoot LC, Seelaar H, Sánchez-Valle R, Laforce R, Graff C, Galimberti D, Vandenberghe R, de Mendonca A, Tiraboschi P, Santana I, Gerhard A, Levin J, Sorbi S, Otto M, Bertoux M, Lebouvier T, Ducharme S, Butler C, Finger E, Tartaglia MC, Masellis M, Rowe JB, Synofzik M, Moreno F, Borroni B, Leber I, Zanusso G, Rohrer JD, Migliaccio R, GENetic Frontotemporal dementia Initiative (GENFI).   +37 more
europepmc   +1 more source

A pathogenic Tau mutation drives autophagy-lysosome dysfunction that limits Tau degradation in a model of frontotemporal dementia. [PDF]

Nat Commun
Mirfakhar FS, Marsh JA, Sato C, Schache KJ, Minaya MA, Dolle RE, Pak SC, Silverman GA, Perlmutter DH, Macauley SL, Karch CM.   +10 more
europepmc   +1 more source

Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau. [PDF]

Sci Adv
Tsefou E, Bez S, Birkle TJY, Foiani M, Watamura N, Bourdenx M, Gavriouchkina D, Turkes E, Crawford S, Coneys R, Isaacs AM, Duff KE.   +11 more
europepmc   +1 more source

Tau A152T risk variant drives distinct cell type transcriptional signatures in AD and PSP. [PDF]

Acta Neuropathol
Lilley MT, Ren Y, Soni D, Sanborn EC, Marks JD, Chen Y, Yan Y, DeTure M, Rawlinson B, Dickson DW, Cook CN.   +10 more
europepmc   +1 more source

CNV-Finder: streamlining copy number variation discovery. [PDF]

Bioinform Adv
Kuznetsov N, Daida K, Makarious MB, Al-Mubarak B, Atterling Brolin K, Malik L, Kouam C, Baker B, Real R, Step K, Lange LM, Wu L, Ostrozovicova M, Andersh KM, Kung PJ, Mecheri Y, Tay YW, Soundous Malek B, Al Tassan N, Periñan MT, Hong S, Koretsky MJ, Sargeant L, Levine K, Blauwendraat C, Billingsley KJ, Bandres-Ciga S, Leonard HL, Bardien S, Morris HR, Singleton AB, Nalls MA, Vitale D.   +32 more
europepmc   +1 more source

Data-driven modelling of tau pathology reveals distinct progressive supranuclear palsy subtypes. [PDF]

Brain
Cullinane PW, Parmera JB, Nelvagal H, Curless T, Chajed LP, Wrigley S, Sifontes Valladares W, Burrows M, Ebanks K, Wu L, Binding LP, Anton J, Revesz T, Real R, Vaughan DP, Jabbari E, Morris HR, Brandner S, Young AL, Hoti G, Ma Y, Bechtawi M, Chiraki N, de Pablo-Fernández E, Lim YM, Warner TT, Jaunmuktane Z.   +26 more
europepmc   +1 more source

RNA-based therapeutics for Alzheimer's disease and related tauopathies: challenges and opportunities. [PDF]

J Prev Alzheimers Dis
Rajbanshi B, Brentari I, Denti MA, Cummings JL, Guruacharya A.   +4 more
europepmc   +1 more source

Tau acetylation at K331 has limited impact on tau pathology in vivo. [PDF]

FEBS Lett
Hashimoto S, Matsuba Y, Takahashi M, Saido TC.   +3 more
europepmc   +1 more source